

Ajanta Pharma

Estimate change	↔
TP change	↔
Rating change	↔

Bloomberg	AJP IN
Equity Shares (m)	125
M.Cap.(INRb)/(USDb)	345.6 / 4
52-Week Range (INR)	3486 / 2022
1, 6, 12 Rel. Per (%)	14/0/17
12M Avg Val (INR M)	470

Financials & Valuations (INR b)

Y/E MARCH	FY25	FY26E	FY27E
Sales	46.5	52.4	59.6
EBITDA	13.2	14.8	17.7
Adj. PAT	9.4	10.5	12.3
EBIT Margin (%)	25.2	25.2	27.1
Cons. Adj. EPS (INR)	74.1	83.6	97.2
EPS Gr. (%)	18.9	11.9	16.2
BV/Sh. (INR)	299.6	362.5	434.9

Ratios

Net D:E	-0.2	-0.2	-0.2
RoE (%)	25.5	25.0	24.4
RoCE (%)	25.9	25.5	24.7
Payout (%)	26.0	26.3	25.5

Valuations

P/E (x)	37.4	33.1	28.5
EV/EBITDA (x)	26.5	23.6	19.3
Div. Yield (%)	0.7	0.8	0.9
FCF Yield (%)	2.5	0.9	2.7
EV/Sales (x)	7.5	6.6	5.7

Shareholding Pattern (%)

As On	Jun-25	Mar-25	Jun-24
Promoter	66.3	66.3	66.3
DII	17.5	17.5	17.4
FII	8.9	8.9	8.4
Others	7.4	7.4	7.9

FII includes depository receipts

CMP: INR2,767

TP: INR3,200 (+16%)

Buy

Consistent growth ahead of industry in DF/Asia

US generics shows revival in growth for two quarters

- Ajanta Pharma (AJP) delivered better-than-expected financial performance for the quarter. It recorded a 5%/8%/9% beat on revenue/EBITDA/PAT for 1QFY26 vs our estimates.
- AJP has consistently outperformed the domestic formulation (DF) market, led by the robust pace of new launches, including first-to-market, scaling up newer therapies, and increasing reach through additional MRs.
- After a moderate YoY growth in FY25, AJP has shown healthy improvement in the US generics segment for the second consecutive quarter.
- AJP is strengthening its presence in Asia by adding products in chronic therapies as well as enhancing its MR resources.
- We largely maintain our estimates for FY26/FY27. We value AJP at 34x 12M forward earnings to arrive at a TP of INR3,260. AJP is a differentiated play, with ~76% of its business in the branded generics segment. It follows a geographic-specific strategy to outpace industry growth in DF/Asia/Africa. It maintains a healthy pace of launches and offers better growth prospects in the US generics segment. Overall, we expect a 15% earnings CAGR over FY25-27. Reiterate BUY.

Product mix benefit offset by higher opex YoY

- AJP's 1QFY26 revenue grew 14% to INR13b (our est: INR12.5b), led by growth across all key businesses.
- DF sales rose 16% YoY to INR4.1b (31% of sales). US generic sales rose 36% YoY to INR3.1b (24% of sales). Branded generics Asia sales rose 10% YoY to INR3b (23% of sales).
- Africa branded generic sales declined 1% YoY to INR2.3b (18% of sales). Africa Institutional sales declined 10% to INR380m (3% of sales).
- Gross margin expanded 220bp YoY to 78.8% due to a better product mix.
- However, EBITDA margin contracted ~260bp YoY to 29% (our est. 28%) as higher gross margins were offset by an increase in employee costs/other costs (up 110bp/390bp YoY as a % of sales).
- Operational costs (employee expense/other expense) have increased at a significantly higher rate than revenue over the past four quarters, driven by MR addition as well as increased marketing/promotional activities for newer therapies.
- Consequently, EBITDA grew 4.5% YoY to INR3.8b (our est. INR3.5b).
- Adjusting for the net forex loss impact of INR158m, Adj. PAT grew 2% YoY to INR2.7b (our est. INR2.5b).

Highlights from the management commentary

- While no ANDA was filed in 1QFY26, AJP has maintained its guidance of 10-12 ANDA filings for the US market in FY26.
- The company aims to sustain a gross margin of 78% (+-1%) for FY26. It indicated maintaining FY26 EBITDA margin at similar levels to those in FY25.
- AJP guided for mid-to-high single-digit YoY growth in the domestic formulation segment in FY26.
- It aims to sustain the US sales run rate on the back of new launches, market share gains, and upcoming launches.

- AJP has taken steps to revive YoY growth in cardiology therapy within the domestic formulation segment, with the impact expected to become visible in the coming quarters.

Consol. - Quarterly perf.

Y/E March	(INR m)											
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE	FY25	FY26E	FY26E	vs Est
Net Sales	11,449	11,866	11,461	11,704	13,027	13,272	13,103	13,007	46,481	52,408	12,454	4.6
YoY Change (%)	12.1	15.4	3.7	11.0	13.8	11.8	14.3	11.1	10.4	12.8	8.8	
Total Expenditure	7,846	8,498	8,253	8,733	9,262	9,449	9,499	9,430	33,330	37,641	8,979	
EBITDA	3,604	3,368	3,208	2,972	3,765	3,822	3,603	3,577	13,152	14,767	3,475	8.4
YoY Change (%)	28.1	15.9	-0.3	6.8	4.5	13.5	12.3	20.4	12.2	12.3	-3.6	
Margins (%)	31.5	28.4	28.0	25.4	28.9	28.8	27.5	27.5	28.3	28.2	27.9	
Depreciation	340	344	360	398	413	380	376	373	1,441	1,542	356	
EBIT	3,264	3,024	2,849	2,574	3,352	3,442	3,228	3,204	11,710	13,225	3,119	
YoY Change (%)	31.5	17.7	-0.9	5.4	2.7	13.8	13.3	24.5	13.0	12.9	-4.4	
Margins (%)	28.5	25.5	24.9	22.0	25.7	25.9	24.6	24.6	25.2	25.2	25.0	
Interest	7	60	79	61	53	66	66	66	207	250	66	
Other Income	182	195	129	111	170	145	165	174	616	653	123	
PBT before EO expense	3,439	3,159	2,898	2,624	3,469	3,521	3,327	3,312	12,119	13,629	3,176	
Extra-Ord expense	-217	-257	176	71	-158	0	0	0	-227	-158	0	
PBT	3,221	2,902	3,074	2,694	3,311	3,521	3,327	3,312	11,892	13,471	3,176	
Tax	764	738	745	442	758	799	765	788	2,688	3,111	715	
Effective Rate (%)	23.7	25.4	24.2	16.4	22.9	22.7	23.0	23.8	22.6	23.1	22.5	
Reported PAT	2,458	2,165	2,329	2,253	2,553	2,722	2,562	2,524	9,204	10,360	2,461	3.7
Adj PAT	2,624	2,356	2,196	2,194	2,675	2,722	2,562	2,524	9,369	10,482	2,461	8.7
YoY Change (%)	30.8	26.5	3.3	16.4	2.0	15.5	16.7	15.0	18.9	11.9	-6.2	
Margins (%)	22.6	19.5	18.9	18.6	20.3	20.3	19.3	19.1	19.9	19.8	19.6	

Key performance Indicators (Consolidated)

Y/E March	(INR m)											
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	FY25	FY26E	FY26E	1QE
INRm												
Domestic formulations	3,530	3,860	3,450	3,700	4,100	4,149	4,039	4,266	14,540	16,554	3,846	
YoY Change (%)	10.7	8.7	12.0	13.5	16.1	7.5	17.1	15.3	11.2	13.9	8.9	
Asia	2,770	2,960	3,160	3,030	3,040	3,315	3,444	3,454	11,944	13,254	3,102	
YoY Change (%)	9.1	28.7	8.2	7.8	9.7	12.0	9.0	14.0	13.0	11.2	12.0	
Africa (branded + Insti)	2,720	2,560	2,060	1,610	2,660	2,675	2,478	2,020	8,902	9,832	2,333	
YoY Change (%)	21.4	31.5	(14.5)	(7.5)	(2.2)	4.5	20.3	25.5	6.7	9.9	(14.2)	
US	2,280	2,320	2,630	3,250	3,100	3,016	3,025	3,185	10,205	12,326	3,055	
YoY Change (%)	7.0	(2.1)	4.4	24.5	36.0	30.0	15.0	(2.0)	5.9	17.6	34.0	
Cost Break-up												
RM Cost (% of Sales)	23.4	22.1	22.5	24.2	21.2	21.7	21.9	22.2	23.0	21.7	23.7	
Staff Cost (% of Sales)	22.2	22.0	23.1	23.9	23.3	23.0	23.5	24.1	22.8	23.5	23.0	
Other Cost (% of Sales)	18.5	22.8	21.8	21.1	22.4	22.0	22.7	22.0	21.1	22.3	20.8	
Gross Margins(%)	76.6	77.9	77.5	75.8	78.8	78.3	78.1	77.8	77.0	78.3	76.3	
EBITDA Margins(%)	31.5	28.4	28.0	25.4	28.9	28.8	27.5	27.5	28.3	28.2	27.9	
EBIT Margins(%)	28.5	25.5	24.9	22.0	25.7	25.9	24.6	24.6	25.2	25.2	25.0	
PBT Margins(%)	29.6	26.2	25.0	22.2	26.3	26.2	25.1	25.1	25.7	25.7	25.3	
PAT Margins(%)	22.6	19.5	18.9	18.6	20.3	20.3	19.3	19.1	19.9	19.8	19.6	

Other highlights from the management commentary

- AJP indicated its intention of adding 250MRs across branded markets of India/Asia/Africa in FY26.
- The segmental mix has been stable QoQ, while the product mix is driving gross margin expansion on a QoQ basis.
- The trade generic business in 1QFY26 was INR390m.
- Given the muted outlook at industry level, AJP indicated some softness in growth prospects of the African business for FY26.
- Capex for FY26 is expected to be INR1.5b-INR2b.



Key exhibits

Exhibit 1: DF sales up ~16% YoY in 1QFY26




Exhibit 2: R&D spending at ~4.3% of sales in 1QFY26




Exhibit 3: Africa sales (Branded + Institutional) declined ~2.2% YoY in 1QFY26




Exhibit 4: Asia sales grew 9.7% YoY in 1QFY26




Exhibit 5: Gross margin expanded 220bp YoY in 1QFY26





Exhibit 6: EBITDA margin contracted ~260bp YoY in 1QFY26



Branded generics drives outperformance; US launches add momentum

Branded generics (73% of Q1FY26 sales) – On-track to beat industry

- In 1QFY26, AJP's DF (branded) revenue grew 19% YoY to ~ INR3.7b. On a 12M basis, the growth was driven by: a) price (+4.4% YoY) and b) volume (+2.5% YoY) and new launches (+3.3% YoY).
- In MAT Jun'25, AJP outperformed the industry by ~230bp, led by superior execution in the derma/pain/anti-diabetic category.
- By foraying into new therapies such as nephrology and gynecology, AJP is broadening its DF portfolio and unlocking fresh growth avenues to continue outperforming the IPM.
- AJP has taken steps to revive YoY growth in cardiology therapy within the domestic formulation segment, offsetting the impact of competition.
- Over FY25-27, we expect AJP to post a 14.4% sales CAGR in the DF segment, driven by a revival in the cardiology segment and the scale-up of new therapies.
- AJP continues to maintain its growth momentum in the Asia branded generics segment, led by a focused approach on chronic therapies and increasing its reach.
- In 1QFY26, the African branded generics business was stable YoY at INR2.3b. For FY26, we anticipate moderate growth, citing a high base effect and subdued outlook at the industry level.
- Accordingly, we expect a 13% sales CAGR in the Asia/Africa branded generics segment over FY25-27, reaching INR25b.

US generics – Product launches/market share gains to fuel growth

- In 1QFY26, US generics revenue grew 36% YoY to INR3.1b. In FY25, the company witnessed moderate YoY growth due to the slower pace of filing and launches, along with price erosion in the base portfolio.
- That said, AJP aims to file 10-12 ANDAs in FY26 and scale up its business from five products launched in 2HFY25.
- For FY26, AJP aims to launch three more products over the medium term, with one product already launched in Q1FY26.
- Accordingly, we build in a 15% sales CAGR over FY25-27 in the US generics market, reaching INR13.9b.

Valuation and view: Reiterate BUY

- We largely maintain our estimates for FY26/FY27. We value AJP at 34x 12M forward earnings to arrive at a TP of INR3,260. AJP is a differentiated play, with ~76% of its business in the branded generics segment. It follows a geography-specific strategy to outpace industry growth in DF/Asia/Africa. It maintains a healthy pace of launches and better growth prospects in the US generics segment. Overall, we expect a 15% earnings CAGR over FY25-27. Reiterate BUY.

Exhibit 7: P/E chart





Exhibit 8: EV/EBITDA chart



Story in charts

Exhibit 9: Total sales to post 13% CAGR over FY25-27E






Exhibit 10: DF sales to clock 14.4% CAGR over FY25-27E



Source: Company, MOFSL

Source: Company, MOFSL

Exhibit 11: EM sales to clock 12% CAGR over FY25-27E




Source: Company, MOFSL

Exhibit 12: US sales to post 15% CAGR over FY25-27E




Source: Company, MOFSL

Exhibit 13: Expect 135bp margin expansion over FY25-27



Source: Company, MOFSL

Exhibit 14: Expect 15% earnings CAGR over FY25-27



Source: Company, MOFSL

Financials and valuations

Consolidated - Income Statement

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Total Income from Operations	20,554	25,879	28,897	33,410	37,426	42,087	46,481	52,408	59,588
Change (%)	-3.5	25.9	11.7	15.6	12.0	12.5	10.4	12.8	13.7
Total Expenditure	14,809	18,895	18,911	23,986	28,972	30,368	33,330	37,641	41,921
% of Sales	72.1	73.0	65.4	71.8	77.4	72.2	71.7	71.8	70.4
EBITDA	5,744	6,983	9,986	9,424	8,454	11,719	13,152	14,767	17,666
Margin (%)	27.9	27.0	34.6	28.2	22.6	27.8	28.3	28.2	29.6
Depreciation	721	957	1,161	1,253	1,308	1,354	1,441	1,542	1,534
EBIT	5,024	6,026	8,825	8,171	7,146	10,365	11,710	13,225	16,133
Int. and Finance Charges	12	119	83	102	58	72	207	250	248
Other Income	211	522	260	757	803	459	616	653	785
PBT bef. EO Exp.	5,223	6,429	9,002	8,826	7,892	10,752	12,119	13,629	16,670
EO Items	80	-211	0	-269	439	-387	227	158	0
PBT after EO Exp.	5,143	6,640	9,002	9,095	7,453	11,139	11,892	13,471	16,670
Total Tax	1,273	1,963	2,463	1,968	1,574	2,978	2,688	3,111	4,377
Tax Rate (%)	24.8	29.6	27.4	21.6	21.1	26.7	22.6	23.1	26.3
Minority Interest	0	0	0	0	0	0	0	0	0
Reported PAT	3,870	4,677	6,539	7,127	5,879	8,162	9,204	10,360	12,292
Adjusted PAT	3,930	4,522	6,539	6,916	6,225	7,878	9,369	10,482	12,292
Change (%)	-16.1	15.1	44.6	5.8	-10.0	26.6	18.9	11.9	17.3
Margin (%)	19.1	17.5	22.6	20.7	16.6	18.7	20.2	20.0	20.6

Consolidated - Balance Sheet

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	175	175	174	172	253	253	251	251	251
Total Reserves	22,277	25,813	29,782	32,472	33,627	35,421	37,652	45,606	54,764
Net Worth	22,452	25,989	29,956	32,644	33,880	35,674	37,903	45,856	55,014
Total Loans	7	7	16	19	15	15	26	26	26
Deferred Tax Liabilities	271	558	421	463	977	1,085	1,105	1,105	1,105
Capital Employed	22,730	26,553	30,393	33,125	34,872	36,773	39,034	46,987	56,145
Gross Block	16,152	20,045	21,896	22,857	24,012	25,191	29,461	32,371	34,753
Less: Accum. Deprn.	4,366	5,324	6,485	7,738	9,046	10,400	11,841	13,383	14,916
Net Fixed Assets	11,786	14,721	15,411	15,120	14,966	14,792	17,620	18,989	19,837
Goodwill on Consolidation	0	0	0	0	0	0	0	0	0
Capital WIP	2,613	1,319	1,082	1,529	2,095	2,565	1,763	1,853	1,271
Total Investments	888	476	517	707	5,465	3,580	4,732	4,732	4,732
Curr. Assets, Loans&Adv.	11,357	16,417	20,276	22,645	24,265	25,448	26,034	33,492	43,901
Inventory	4,357	4,957	7,665	7,911	8,156	8,284	9,039	11,034	13,208
Account Receivables	4,595	7,753	7,384	10,198	10,569	12,468	11,827	15,794	17,142
Cash and Bank Balance	1,005	2,053	2,096	2,118	3,309	1,308	1,762	2,444	8,755
Loans and Advances	1,400	1,655	3,131	2,418	2,231	3,388	3,406	4,219	4,797
Curr. Liability & Prov.	3,913	6,379	6,893	6,875	11,919	9,611	11,116	12,077	13,595
Account Payables	2,251	3,623	3,739	3,272	4,227	4,633	4,542	5,878	6,547
Other Current Liabilities	1,278	2,230	2,858	3,302	7,310	4,405	5,537	5,486	6,237
Provisions	384	526	296	301	382	573	1,036	714	811
Net Current Assets	7,444	10,038	13,383	15,770	12,346	15,836	14,919	21,414	30,306
Appl. of Funds	22,730	26,553	30,393	33,126	34,872	36,773	39,033	46,987	56,145

Financials and valuations

Ratios

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Basic (INR)									
EPS	31.1	35.7	51.7	54.7	49.2	62.3	74.7	83.6	97.2
Cash EPS	36.8	43.3	60.9	64.6	59.5	73.0	85.5	95.0	109.3
BV/Share	177.5	205.4	236.8	258.1	267.8	282.0	299.6	362.5	434.9
DPS	6.3	9.0	6.6	6.4	11.5	15.4	18.9	21.5	24.8
Payout (%)	20.6	24.8	12.7	11.4	24.7	23.8	26.0	26.3	25.5
Valuation (x)									
P/E	89.2	77.5	53.6	50.7	56.3	44.5	37.4	33.1	28.5
Cash P/E	75.4	64.0	45.5	42.9	46.5	38.0	32.4	29.2	25.4
P/BV	15.6	13.5	11.7	10.7	10.3	9.8	9.2	7.6	6.4
EV/Sales	17.0	13.5	12.1	10.4	9.3	8.3	7.5	6.6	5.7
EV/EBITDA	60.8	49.9	34.9	37.0	41.1	29.8	26.5	23.6	19.3
Dividend Yield (%)	0.2	0.3	0.2	0.2	0.4	0.6	0.7	0.8	0.9
FCF per share	-1.9	15.6	34.5	29.0	48.8	51.1	66.5	23.7	70.4
Return Ratios (%)									
RoE	18.3	18.7	23.4	22.1	18.7	22.7	25.5	25.0	24.4
RoCE	18.4	19.0	23.6	22.3	18.8	22.8	25.9	25.5	24.7
RoIC	21.4	20.7	25.9	23.1	21.4	28.5	30.2	29.6	30.0
Working Capital Ratios									
Inventory (Days)	77	66	97	86	80	72	71	77	81
Debtor (Days)	82	109	93	111	103	108	93	110	105
Creditor (Days)	40	51	47	36	41	40	36	41	40
Leverage Ratio (x)									
Net Debt/Equity	-0.1	-0.1	-0.1	-0.1	-0.3	-0.1	-0.2	-0.2	-0.2

Consolidated - Cash Flow Statement

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
OP/(Loss) before Tax	5,303	6,218	9,002	8,557	7,453	11,139	11,892	13,786	16,670
Depreciation	721	957	1,161	1,253	1,308	1,354	1,441	1,542	1,534
Interest & Finance Charges	-199	-403	-177	-655	58	72	207	-403	-537
Direct Taxes Paid	-1,273	-1,963	-2,463	-1,968	-1,513	-3,121	-3,230	-3,111	-4,377
(Inc)/Dec in WC	115	-1,548	-1,708	-2,427	665	-998	1,789	-5,814	-2,581
CF from Operations	4,667	3,262	5,815	4,760	7,971	8,446	12,100	6,001	10,708
Others	-922	1,306	169	323	-53	-596	-521	0	0
CF from Operating incl EO	3,745	4,568	5,983	5,082	7,918	7,851	11,579	6,001	10,708
(Inc)/Dec in FA	-3,979	-2,599	-1,614	-1,409	-1,745	-1,390	-3,168	-3,000	-1,800
Free Cash Flow	-234	1,969	4,369	3,674	6,173	6,460	8,411	3,001	8,908
(Pur)/Sale of Investments	1,155	413	-41	-190	-3,907	1,774	-977	0	0
Others	596	-58	-1,169	857	56	270	378	653	785
CF from Investments	-2,228	-2,244	-2,824	-741	-5,596	654	-3,767	-2,347	-1,015
Issue of Shares	0	0	-2	-2	-14	0	0	0	0
Inc/(Dec) in Debt	-5	1	9	3	-5	1	11	0	0
Interest Paid	-12	-119	-83	-102	-23	-35	-173	-250	-248
Dividend Paid	-796	-1,159	-829	-816	-897	-6,422	-3,494	-2,722	-3,135
Others	-664	-405	-1,832	-3,873	-192	-4,054	-3,163	0	0
CF from Fin. Activity	-1,476	-1,683	-2,737	-4,790	-1,131	-10,511	-6,819	-2,972	-3,383
Inc/Dec of Cash	41	640	422	-449	1,191	-2,006	993	682	6,310
Opening Balance	906	952	1,592	2,014	1,565	2,757	750	1,743	2,425
Closing Balance	948	1,592	2,014	1,565	2,757	750	1,743	2,425	8,735
Unrealised loss / (gain) on forex	4	432	82	14	14	19	19	19	19

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may: (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal Capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal Capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no warranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dp@motilaloswal.com.